Treatment News : ID Docs Widely Support PrEP, Yet Only 9% Write Scripts

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » December 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


December 18, 2013

ID Docs Widely Support PrEP, Yet Only 9% Write Scripts

Three out of four infectious disease physicians in the United States and Canada support the use of HIV antiretrovirals (ARVs) as pre-exposure prophylaxis (PrEP), yet a scant 9 percent report prescribing to HIV-negative patients this method of HIV prevention, aidsmap reports. Publishing their findings in the online edition of Clinical Infectious Diseases, investigators conducted the largest-ever survey of attitudes toward PrEP among clinicians.

In June 2013, the researchers gave a questionnaire to 1,175 physician members of the Infectious Disease Society of America’s (IDSA) Emerging Infections Network (EIN). The survey’s response rate was 49 percent. Seventy-four percent of the responding clinicians supported PrEP, while 14 percent were unsure and 12 percent were unsupportive.

Nine percent reported prescribing PrEP. Forty-three percent said that while they had not yet written a prescription for the therapy they would do so. Thirty-four percent said that PrEP was not relevant to their patient population.

Reasons for doctors’ lack of support for prescribing PrEP included worries about how their patients would adhere to the therapy, and whether drug resistance may come about. There were also worries about the drug’s cost and insurance coverage, about giving a potentially toxic medication to HIV-negative people, and concerns about PrEP’s efficacy in preventing HIV transmission. Some were also worried about risk compensation among their patients—the phenomenon of people engaging in more risky behaviors because of an intervention that otherwise lowers their risk, likely mitigating if not canceling out the benefit of the intervention.

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, pre-exposure prophylaxis, PrEP, infectious disease physician, aidsmap, prescriptions, Infectious Disease Society of America, IDSA, Emerging Infections Network, EIN, risk compensation.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.